Characteristics of AML patients with enhanced and normal serum tryptase levels
| . | Serum tryptase no greater than 15 ng/mL . | Serum tryptase greater than 15 ng/mL . |
|---|---|---|
| No. of patients | 80 | 53 |
| Age, y; median (range) | 62.5 (16-89) | 62.0 (24-86) |
| Hemoglobin, g/dL; median (range) | 9.1 (5.8-14.8) | 8.8 (6.3-12.7) |
| WBC, cells/μL; median (range) | 9665 (34-251 870) | 17 900 (900-261 610) |
| Peripheral blasts, %; median (range) | 18 (0-97) | 44 (0-96) |
| Basophils, %; median (range) | 0 (0-17) | 0 (0-10) |
| LDH, U/L; median (range) | 324 (128-6820) | 443 (133-4580) |
| Histamine, ng/mL; median (range) | 9.2 (0.3-273) | 16.6 (0.5-289) |
| FAB groups, n (%) | ||
| AML M0 | 3 (3.8) | 6 (11.3) |
| AML M1 | 13 (16.3) | 7 (13.2) |
| AML M2 | 5 (6.3) | 9 (17.0) |
| AML M3 | 2 (2.5) | 4 (7.5) |
| AML M4 | 20 (25.0) | 6 (11.3) |
| AML M4 eo | 0 (0.0) | 7 (13.2) |
| AML M5 | 16 (20.0) | 2 (3.8) |
| AML M6 | 5 (6.3) | 0 (0.0) |
| AML M7 | 2 (2.5) | 1 (1.9) |
| Secondary AML | 14 (17.5) | 11 (20.8) |
| Cytogenetics, n (%) | ||
| inv(16) | 0 (0.0) | 7 (13.2) |
| t(8;21) | 0 (0.0) | 2 (3.7) |
| t(15;17) | 2 (2.5) | 4 (7.5) |
| Normal | 35 (43.8) | 18 (34.0) |
| Other | 17 (21.3) | 8 (15.1) |
| Complex | 19 (23.8) | 10 (18.9) |
| Not available | 7 (8.8) | 4 (7.5) |
| . | Serum tryptase no greater than 15 ng/mL . | Serum tryptase greater than 15 ng/mL . |
|---|---|---|
| No. of patients | 80 | 53 |
| Age, y; median (range) | 62.5 (16-89) | 62.0 (24-86) |
| Hemoglobin, g/dL; median (range) | 9.1 (5.8-14.8) | 8.8 (6.3-12.7) |
| WBC, cells/μL; median (range) | 9665 (34-251 870) | 17 900 (900-261 610) |
| Peripheral blasts, %; median (range) | 18 (0-97) | 44 (0-96) |
| Basophils, %; median (range) | 0 (0-17) | 0 (0-10) |
| LDH, U/L; median (range) | 324 (128-6820) | 443 (133-4580) |
| Histamine, ng/mL; median (range) | 9.2 (0.3-273) | 16.6 (0.5-289) |
| FAB groups, n (%) | ||
| AML M0 | 3 (3.8) | 6 (11.3) |
| AML M1 | 13 (16.3) | 7 (13.2) |
| AML M2 | 5 (6.3) | 9 (17.0) |
| AML M3 | 2 (2.5) | 4 (7.5) |
| AML M4 | 20 (25.0) | 6 (11.3) |
| AML M4 eo | 0 (0.0) | 7 (13.2) |
| AML M5 | 16 (20.0) | 2 (3.8) |
| AML M6 | 5 (6.3) | 0 (0.0) |
| AML M7 | 2 (2.5) | 1 (1.9) |
| Secondary AML | 14 (17.5) | 11 (20.8) |
| Cytogenetics, n (%) | ||
| inv(16) | 0 (0.0) | 7 (13.2) |
| t(8;21) | 0 (0.0) | 2 (3.7) |
| t(15;17) | 2 (2.5) | 4 (7.5) |
| Normal | 35 (43.8) | 18 (34.0) |
| Other | 17 (21.3) | 8 (15.1) |
| Complex | 19 (23.8) | 10 (18.9) |
| Not available | 7 (8.8) | 4 (7.5) |
WBC indicates white blood cell; LDH, lactate dehydrogenase; FAB, French-American-British; AML, acute myeloid leukemia.